Business Context and Reporting Period
Company: Summit Therapeutics plc (Summit Therapeutics Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended January 31, 2016
Business Overview: Summit is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI). The company has no commercial product revenue and relies on equity financing and grants to fund operations.
Key Financial Metrics
| Metric | 2016 (USD) | 2016 (GBP) | 2015 (GBP) |
|---|---|---|---|
| Other Operating Income | $2,058 | £1,451 | £2,148 |
| Operating Loss | $(28,617) | £(20,176) | £(12,711) |
| Net Loss | $(24,238) | £(17,088) | £(11,363) |
| Loss Per Share (Basic/Diluted) | $(0.41) | £(0.29) | £(0.29) |
| Cash and Cash Equivalents | $23,125 | £16,304 | £11,265 |
| Total Assets | $35,565 | £25,076 | £19,396 |
| Total Equity | $29,974 | £21,133 | £14,966 |
| Accumulated Deficit | N/A | £(47,343) | £(30,255) |
Note: USD figures are translated at the rate of £1.00 = $1.4184 as of January 29, 2016.
Material Changes vs. Prior Period
- Increased Operating Loss: Operating loss increased by 58.7% (from £12.7 million to £20.2 million) primarily due to a 61.8% increase in Research and Development (R&D) expenses.
- R&D Expense Growth: Total R&D expenses rose to £16.9 million from £10.4 million.
- DMD Program: Expenses increased by £2.8 million to £7.5 million, driven by clinical activities for ezutromid and the University of Oxford alliance.
- CDI Program: Expenses increased by £2.3 million to £5.6 million, driven by Phase 2 clinical trial costs and Phase 3 preparation.
- Decline in Grant Income: Other operating income decreased by 32.5% to £1.5 million, largely due to a lower contribution rate from the Wellcome Trust as Phase 2 activities replaced Phase 1 activities.
- Improved Tax Credit: Income tax credit increased by 135.8% to £3.1 million, reflecting higher R&D expenditure eligible for UK tax credits.
- Cash Position: Cash and cash equivalents increased by £5.0 million to £16.3 million, supported by a £22.1 million net inflow from financing activities (equity sales).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Going Concern: The independent auditor has included an explanatory paragraph regarding the company's ability to continue as a going concern due to significant losses, negative cash flows, and an accumulated deficit.
- Cash Runway: Management believes existing cash resources are sufficient to fund operations through the end of the fiscal year ending January 31, 2017. This is expected to cover:
- Reporting of 24-week muscle biopsy data from the PhaseOut DMD trial (expected Jan 2017).
- Top-line data from the Phase 1 optimized formulation of ezutromid (expected Q3 2016).
- Top-line data from the exploratory ridinilazole vs. fidaxomicin trial (expected H2 2016).
- Capital Needs: The company does not expect current resources to be sufficient to complete the PhaseOut DMD clinical trial. Additional financing will be required via equity offerings, collaborations, or grants.
Risks and Contingencies
- Clinical Trial Uncertainty: Success depends on the safety and efficacy of ezutromid (DMD) and ridinilazole (CDI). Previous trials showed variable plasma levels of ezutromid, though a modified diet improved absorption. No placebo-controlled reduction in CK (muscle damage marker) was observed in the most recent Phase 1b trial.
- Regulatory Approval: No product candidates have received marketing approval. Regulatory pathways for DMD are complex with limited clinical trial experience.
- Competition: Significant competition exists in both DMD (e.g., PTC Therapeutics, BioMarin, Sarepta) and CDI (e.g., Merck/Cubist, Actelion) markets.
- Intellectual Property: Ridinilazole lacks composition-of-matter patent protection for the active pharmaceutical ingredient alone, relying on formulation and method-of-treatment patents.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the £16.3 million cash balance against the projected burn rate to reach the January 2017 milestone.
- PhaseOut DMD Trial: Monitor enrollment progress and the upcoming January 2017 muscle biopsy data, which is critical for proving concept.
- Ridinilazole Phase 3: Assess the timeline and cost for advancing ridinilazole to Phase 3 following the positive Phase 2 results.
- Grant Milestones: Review the specific milestones required to unlock remaining funding from the Wellcome Trust (£0.1 million) and Innovate UK (£0.6 million).
- Dilution Risk: Evaluate the potential dilution to shareholders if the company must raise additional capital to complete the PhaseOut DMD trial.